Massachusetts-based Azurity Pharmaceuticals announced July 10 it had received FDA approval for Katerzia Oral Suspension, making the drug the first and only FDA-approved amlodipine oral suspension to hit the commercial market.
Katerzia, a calcium channel blocker, was approved to treat hypertension in adults and pediatric patients aged 6 and up, as well as coronary artery disease in adults. The 1 mg/mL solution offers a ready-to-use, liquid alternative to amlodipine that’s easier for younger patients to stomach.
“We are pleased to announce the FDA approval of Katerzia,” Neal Muni, MD, president and CEO of Azurity Pharmaceuticals, said in a statement. “The addition of Katerzia complements our existing pediatric hypertension portfolio and will strengthen the overall offering from Azurity.”
Katerzia, according to the company’s statement, will be available through an “extensive” network of pharmacies and qualified mail order service.